Exportin 1 inhibition as antiviral therapy
Related Experiment Video
Updated: Dec 17, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Md Hafiz Uddin1, Jeffrey A Zonder1, Asfar S Azmi1
1Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Abstract:
Coronavirus 2019 (COVID-19; caused by Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV-2) is a currently global health problem. Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the nucleus of host cell and reduce virus replication and immunopathogenicity. These observations support the concept of the inhibition of nuclear export as an effective strategy against an array of viruses, including influenza A, B, and SARS-CoV. Clinical studies using the XPO1 inhibitor selinexor as a therapy for COVID-19 infection are in progress.
Insights
Exportin 1 (XPO1) inhibitors, initially for cancer, show promise in blocking viral replication by trapping viral components in the host cell nucleus. Clinical trials are underway to evaluate XPO1 inhibitors for treating COVID-19 infections.
Area of Science:
- Virology
- Oncology
- Cell Biology
Background:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes the global health crisis, COVID-19.
- Exportin 1 (XPO1) is a key protein involved in nucleocytoplasmic transport.
- XPO1 inhibitors have been developed as anticancer agents.
Purpose of the Study:
- To investigate the potential of inhibiting nuclear export as a therapeutic strategy against viral infections, including SARS-CoV-2.
- To explore the repurposing of XPO1 inhibitors for treating COVID-19.
Main Methods:
- Blocking nucleocytoplasmic transport using XPO1 inhibitors.
- Quarantining viral accessory proteins and genomic materials within the host cell nucleus.
- Evaluating the reduction in virus replication and immunopathogenicity.
Main Results:
- Previous studies demonstrated that XPO1 inhibition can reduce replication and immunopathogenicity of various viruses.
- Blocking XPO1 effectively sequesters viral components in the nucleus, limiting their spread.
- XPO1 inhibitors show potential for broad-spectrum antiviral activity.
Conclusions:
- Inhibition of nuclear export via XPO1 is a viable strategy against viral infections like SARS-CoV-2.
- XPO1 inhibitors represent a promising therapeutic avenue for COVID-19.
- Ongoing clinical studies are assessing the efficacy of selinexor, an XPO1 inhibitor, for COVID-19 treatment.
Related Concept Videos
Enzyme Inhibition
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Retroviruses
Retrovirus Life Cycles

